Biotek-snakken — Oktober 2021
-
Det er ikke afgjort endnu https://finance.yahoo.com/news/evaxion-biotech-announces-filing-registration-114900456.html
-
Amerikansk medicinalkæmpe har tocifret vækst Amerikansk medicinalkæmpe har tocifret vækst
-
Xbrane announces four more patents granted https://xbrane.com/en/mfn_news_en/xbrane-announces-four-more-patents-granted/
-
Ja, Fandel…alt kører efter planen…så det er vist bare med at holde ved, selvom kursen svinger meget.
XBrane leverer ihvertfald varen, så mon ikke vi bliver belønnet på den lange bane. -
ArcticZymes Technologies Q3 2021 Results
Tromsø, Norway, 28th October 2021 –
ArcticZymes Technologies (OSE: AZT) reported sales of NOK 25.6 million (19.5) and an EBITDA of NOK 9.0 million (7.1) for the third quarter of 2021.Highlights from Q3 2021
ArcticZymes Technologies (AZT) had Q3 sales of NOK 25.6 million – an increase of 31% (Q3 2020: NOK 19.5 million)
Coronavirus-related sales are estimated at NOK 2.9 million (Q3 2020: NOK 4.0 million)
Gross profit increased to NOK 24.1 -
Formålet med tislelizumab siger de er at øge responsraten og duration - og i den forbindelse synes jeg bare, at jeg husker Ali siger noget om at data først forventes i 2022. Måske fordi man vil have større indblik i duration, men det kan også være jeg forveksler det med noget data i brystkræft
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind